Slovenia Pharmaceuticals & Healthcare Report Q3 2014

May 19, 2014 - Business Monitor International - 96 pages
Abstract Table of Contents Request Details Related
PRINT & SHARE
BMI View: Political instability caused by the collapse of the coalition government and the resignation by the prime minister has increased the risk of a slowdown in GDP growth and a likely loss of momentum in structural reforms. Therefore, the burden of healthcare cuts, under pressure from the EU and IMF, will fall on the pharmaceutical industry. Although public healthcare funding had managed to eliminate its deficit in 2013, undertaking healthcare reform has proved to be politically difficult: two health ministers have resigned since November 2013. As a result, we continue to believe pharmaceutical and healthcare spending will continue to decline this year and the next, before showing modest growth in 2016.

Headline Expenditure Projections

Pharmaceuticals: EUR720mn (US$960mn) in 2013 to EUR700mn (US$920mn) in 2014; +2.1% in local currency terms and -3.4% in US dollar terms.

Healthcare: EUR3.21bn (US$4.26bn) in 2013 to EUR3.13bn (US$4.09bn) in 2014; -2.6% in local currency terms and -3.9% in US dollar terms.

Risk/Reward Rating

Slovenia's Pharmaceutical Risk/Reward Rating score for Q314 stands at 50.4 out of a total of 100, below the regional average of 51.6. A worsening political and economic outlook has impacted Slovenia's RRR score.

Key Trends & Developments

Slovenia's system of basing the price of a patented medicine on a group of medicines in the same therapeutic class, including generics was highlighted in the Pharmaceutical Research and Manufacturers of America's Special 301 submission to the United States Trade Representative in April 2014.

The Competition Protection Agency (CPA) in 2014 will review health sector where the claims of bid rigging for public procurement contracts had been claimed, according to the EU review of Slovenia's policies in February 2014.

In April 2014, a UK court has ordered Anglo-Swedish drugmaker AstraZeneca to pay EUR21mn (USD28.9mn) in damages and court expenses to Slovenian generic drugmaker Krka in a lawsuit...

The Slovenia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Slovenia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovenian pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Slovenia to test other views - a key input for successful budgeting and strategic business planning in the Slovenian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Slovenian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Slovenia.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.


Order This Report

EASY ORDERING
Once you’ve selected your preferred license option, hit ‘order now’ to complete the checkout process using any major credit card, check or wire/bank transfer.
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away


About the Publisher
Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including Daily Alerts, monthly regional Insights, and in-depth quarterly Country Forecast Reports.